RMAT designation enables intensified FDA engagement and potential accelerated pathways, implying preliminary clinical evidence for RTx-015 despite absent peer-reviewed efficacy details, endpoints, and ...
The FDA granted regenerative medicine advanced therapy designation to RTx-015 for the treatment of retinitis pigmentosa.
Background/aims Ocular surface infections remain a major cause of visual loss worldwide, yet diagnosis often relies on slow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results